

**Title:** *RPGR*-associated Retinopathy – Clinical Features, Molecular Genetics, Animal Models and Therapeutic Options

**Authors:** James J.L.Tee,<sup>1,2</sup> Alexander J. Smith,<sup>1,2</sup> Alison J. Hardcastle,<sup>1,2</sup> and Michel Michaelides,<sup>1,2</sup>

1. UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK
2. Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK

**Corresponding Author:**

Michel Michaelides, UCL Institute of Ophthalmology, 11-43 Bath Street, London, EC1V 9EL, UK. *E-mail:* [michel.michaelides@ucl.ac.uk](mailto:michel.michaelides@ucl.ac.uk) *Tel.no.* +44 207 608 6864

**Key words (MeSH terms):** Retinal Diseases; Retinal Cone Photoreceptor Cells; Retinal Rod Photoreceptor Cells; Genetic Therapy; Review; *RPGR*

## **Abstract**

Retinitis Pigmentosa GTPase Regulator (*RPGR*) gene sequence variants account for the vast majority of X-linked Retinitis Pigmentosa (RP), which is one of the most severe forms of RP. Symptoms of nyctalopia typically begin in childhood, with increasing loss of peripheral visual field during teenage years, and progressive central visual loss during the second to fourth decade of life. There is however marked intra- and interfamilial phenotypic heterogeneity both in affected males and carrier females. There is now a far greater understanding of the range of phenotypes associated with variants in this gene; including rod-cone dystrophy, cone-rod dystrophy, cone dystrophy, macular dystrophy and non-ocular phenotypes. There are also increasingly established genotype-phenotype associations and structure-function correlations. *RPGR* is involved in ciliary function, with ciliary dysfunction now recognized as the mechanism underlying a large proportion of inherited retinal disease. There has been significant progress in both identifying naturally occurring animal models and developing novel models to define the underlying disease mechanisms and to test gene replacement therapy, in addition to advances in human retinal imaging, culminating in completed and planned clinical trials. These significant developments will be discussed.

## **Introduction**

Hereditary retinal disorders are now the leading cause of blindness in working age adults in England and Wales, and the second commonest in childhood [1]. Retinitis pigmentosa (RP), a group of genetically and phenotypically diverse disorders, affects ~ 1:3000 to 1:4000 and is inherited as an autosomal dominant, recessive or X-linked (XL) trait; which are estimated to account for 30-40%, 45-60% and 5-15% of cases respectively [2-6]. X-linked retinitis pigmentosa (XLRP) is particularly severe, with early-onset in childhood, progressing to severe visual impairment by the third to fourth decade. Retinitis Pigmentosa GTPase Regulator (*RPGR*) gene sequence variants account for 70-80% of XLRP [7-9], *RP2* variants for a further 5-20% [8-12], and a third gene, *OFD1* has been identified as a rare cause of XLRP [13]. This review focuses on the molecular genetics and phenotypic features of *RPGR* retinopathy, animal models and therapeutic options.

## **Molecular Genetics of *RPGR***

*RPGR* was first identified as a cause of XLRP in 1996, composed of 19 exons and encoding a 90kDa protein product, with exons 2-11 coding for a structure similar to regulator of chromosome condensation 1 (RCC1) at the N-terminus [7 14]. RCC1 is a well-characterised protein that functions as a guanine nucleotide exchange factor for Ran (a Ras-related nuclear protein) and is thought to play an important role in nucleo-cytoplasmic transport and regulation of cell division [15 16]. Further analysis identified a transcript with a novel 3' terminal exon known as exon open reading frame 15 (ORF15) that includes exon 15 and a portion of intron 15 [17]. Only 10-20% of patients with XLRP harboured disease-causing sequence variants in *RPGR* prior to

the discovery of ORF15. The ORF15 exon has an unusual repetitive sequence encoding 567 amino acids rich in glycine and glutamic acid residues that is a “mutational hotspot”, harbouring approximately 60% of all XLRP variants, thus underlying the majority of XLRP [17]. To date, over 300 variants have been identified in *RPGR* [18 19].

There are multiple *RPGR* isoforms arising from alternative splicing [20-24] or post-translational modification [25]. These isoforms are expressed in different amounts in different tissues (lung, kidney, retina, brain, testis); suggesting tissue-specific splicing with tissue-specific functions. The two major *RPGR* isoforms are the constitutive *RPGR* exon 1-19 and *RPGR* ORF15 [16], with *RPGR* ORF15 representing the isoform that is most highly expressed in retina [17]. To the best of our knowledge, all disease-causing variants are found in exons present in isoform *RPGR* ORF15, with only one in exons 15-19 [26], supporting the importance of the *RPGR* ORF15 isoform in the retina.

### **RPGR Interacting Proteins and Function**

*RPGR* comprises an RCC1-like domain at its N-terminus, and the predicted function of the unusual C-terminal ORF15 protein sequence is not known. As illustrated in Figure 1, *RPGR* is localised predominantly to the photoreceptor connecting cilium [24], which is the equivalent of the transition zone of motile and primary cilia. An *RPGR* protein interaction network has been established, either through genetic studies identifying disease genes with overlapping symptoms, or through targeted functional studies, or a combination of both [16 27-29]. Some of the principal interacting proteins will be alluded to herein. Retinitis pigmentosa GTPase regulator-

interacting protein (RPGRIP1) localizes to the connecting cilia and is thought to hold RPGR in this locale [28]. Similarly, retinitis pigmentosa GTPase regulator-interacting protein-1 like protein (RPGRIP1L), delta subunit of rod cyclic GMP phosphodiesterase (PDE $\delta$ ), structural maintenance of chromosomes 1 and 3 (SMC1/3), GTPase Rab8A, nephrocystin-5, and whirlin also have been shown to interact with RPGR [29-35].

Although the function of RPGR is not fully understood, information from biochemical studies and the phenotypes in patients and animal models, strongly suggests that it plays a role in the transport of phototransduction components and other outer segment proteins across the connecting cilium. Biochemical studies have shown that RPGR-ORF15 localises to the connecting cilium of the photoreceptor and binds to the basal body and the axoneme [30-36]. Involvement of RPGR-ORF15 in transport is suggested in immunoprecipitation experiments that show that RPGR interacts with  $\gamma$ -tubulin, subunits of Kinesin II and dynein microtubule motor protein complexes, and intraflagellar transport polypeptide 88 (IFT88) [30]. However, these interactions do not exclude that RPGR-ORF15 may be involved as cargo in these processes, rather than as an active component.

The most prominent and consistent evidence for a role in ciliary transport is provided by various post-mortem studies that have utilised immunohistochemical techniques to demonstrate opsin mislocalisation within the photoreceptor structure in human, canine and mice models of RPGR-deficient carriers and affected subjects [37-41]. Opsin molecules are G-protein coupled receptors integral to visual phototransduction. These are assembled within the organelles of the photoreceptor inner segment and systematically transported via the connecting cilium to their final

destination in the outer segment where they are contained within the disc membranes [42].

Cone and rod opsin mislocalisation to photoreceptor inner segments, perinuclear regions and synaptic terminals has been shown in human and canine subjects [37 40 41]. Cone but not rod opsin mislocalisation to similar regions have also been found in mice models, together with a reduction in rhodopsin levels within the outer segments [38 39].

The structure of the connecting cilium is not compromised in RPGR-deficient photoreceptors, and the presence of correctly localised opsins and relatively well preserved vision in the early stages of disease indicate that RPGR plays a facilitative rather than an essential role in the transport process [39]. A role in docking and selection of cargo at the basal body has been suggested [30 36].

How opsin mislocalisation affects photoreceptor viability to cause retinal degeneration remains unclear. A mechanism whereby ectopic G-protein activity is stimulated by mislocalised opsin molecules leading to photoreceptor apoptosis has been postulated but retinal degeneration has also been shown to occur despite G-protein inactivation [43 44]. However, a causal link between opsin mislocalisation and subsequent retinal degeneration has not been proven and it is possible that photoreceptor viability is affected by other molecular pathways unrelated to opsin mislocalisation, which in itself may simply be a marker of ensuing retinal degeneration.

The amino acid sequence of RPGR provides a clue to its function [14]. The main recognisable feature is its RCC1 homology domain that suggests a function as a guanine nucleotide exchange factor for Ran (a Ras-related nuclear protein) and

catalysis of RanGTP [15]. RanGTP serves as an energy source for molecular motors that move cargo through the nuclear pore complex. The resultant high local concentration of RanGTP in the connecting cilium as generated by RPGR could enable a putative RanGTP-dependent process that drives unidirectional movement of opsins across the connecting cilium to the outer segment [39 45].

### **RPGR Animal Models**

Two naturally occurring *RPGR* ORF15 mutations in the Siberian husky canine breed result in distinct phenotypes. A 5-nucleotide deletion in *RPGR* ORF15 (del1028-1032) gives rise to a premature stop codon and truncation of 230 residues, resulting in X-linked Progressive Retinal Atrophy 1 (XLPRA1) secondary to loss of RPGR function [46]. This phenotype is characterised by gradual photoreceptor degeneration that is post-developmental in onset, affecting rods more than cones, in keeping with human RP, albeit with slower progression. Optical coherence tomography (OCT) demonstrates normal outer nuclear layer (ONL) thickness up to 28 weeks of age, while at older ages (from 56 weeks) ONL thickness starts to decline in the inferior retina while initially remaining preserved at the visual streak [47]. The second more severe phenotype, XLPRA2, is caused by a 2-nucleotide deletion in ORF15 (del1084-1085), downstream to the first, resulting in frameshift and the inclusion of 34 basic amino acids with truncation of 161 residues [46]. OCT demonstrates a generalised decline in ONL thickness that is worse at the cone-rich central visual streak than the periphery [47].

It has been proposed that the early onset of disease in XLPRA2 from around 5 weeks, with rapid progression affecting both rods and cones, may be caused by a

toxic gain of function from an accumulation of abnormal protein product in the endoplasmic reticulum [40 46]. However, the treatment effect shown after adeno-associated viral (AAV) vector mediated *RPGR* gene transfer in these animals [47] argues against a gain of function mechanism. The finding that two distinct phenotypic expressions of XLPRA are related to the exact nature and position of the ORF15 mutations [46] appears to be confirmed by genotype-phenotype correlations in patients as discussed below [9].

Three mouse models of *RPGR* deficiency exist. In the first, generated by the deletion of *RPGR* exons 4-6 [39], cone opsin mislocalisation to inner segments, nuclear and synaptic regions was seen and rhodopsin levels were reduced in rods when examined 20 days postnatally. Retinal structure however was comparable to wild-type and electroretinogram (ERG) function was within normal limits despite a lack of *RPGR*. However, by 6 months, photoreceptor cell loss was apparent [39]. This model demonstrates a slow retinal degeneration, not dissimilar to XLPRA1, and therefore does not emulate the severe degeneration in humans [46]. One of the major shortfalls of murine models to recapitulate human disease is a predominance of rods over cones. In addition, there may not have been a total absence of *RPGR* protein product as residual *RPGR* ORF15 isoform was reported to be present in this model [30]. However, two further mouse models, one a naturally occurring 32 base pair duplication in ORF15 [38], the other an engineered deletion of exon 1 [48], show very similar phenotypes to the original knock-out mice. As these models do not appear to have residual *RPGR* protein, it is unlikely that the putative presence of remaining protein causes the relatively slow rate of degeneration in the murine retina.



### **RPGR Clinical Phenotypes**

Disease-causing sequence variants have been identified in *RPGR* in association with a range of phenotypes including rod-cone dystrophy or retinitis pigmentosa (RP), cone dystrophy (COD), cone-rod dystrophy (CORD), macular atrophy, and rarely syndromic XLRP. RP and CORD are the commonest and best described conditions, so genotype-phenotype correlations will be discussed. The vast majority of retinal disease-causing mutations are loss-of-function alleles, with the majority of these being protein truncations in ORF15.

### ***RPGR Retinitis Pigmentosa (Rod-Cone Dystrophy)***

XLRP is one of the most severe forms of RP, with nyctalopia in most affected males before ten years of age and progression to legal blindness by the third to fourth decade [49]. Myopia, retinal and electrophysiological abnormalities are often present from childhood [49 50]. Most carrier females are asymptomatic or mildly affected, with a minority of females as severely affected as males [50-52]. A significant proportion of carrier females can be identified on the basis of a tapetal reflex seen clinically and/or with fundus autofluorescence (FAF) imaging, and/or generalised retinal dysfunction on electrophysiological testing.

A parafoveal hyperautofluorescent ring is present in some male patients on FAF imaging [53-55]. There is good correlation between ring radius and pattern ERG P50 amplitude (measure of macular function), indicating greater preservation of function with larger rings; this ring constricts over time and thereby may be a

measure of rate of progression both in the clinic and as an end-point for clinical trials [53-55].

An OCT-based 'transition zone' model has been described with progression from an intact foveal centre to diseased periphery, evidenced first by outer segment shortening, followed by decreased ONL thickness and further outer segment loss, preceding inner segment ellipsoid zone (EZ) band disappearance [56]. Annual width decrease of the EZ band was estimated at 248  $\mu\text{m}/\text{year}$  in a group of 28 XLRP patients [57]. Functional correlates have been probed, using static perimetry, in 40 patients with *RPGR* XLRP, with demonstration of greatest rate of decline in retinal sensitivity located at the edges of EZ band disappearance [58].

Sharon *et al* [9] screened *RP2* and *RPGR* in 187 unrelated male patients and their affected relatives, and identified disease-causing variants in 16 and 156 patients respectively, with 71% (111/156) of *RPGR* mutations in ORF15. Age-matched patients with *RPGR* ORF15 sequence variants had milder disease compared with patients with *RPGR* exon 1-14 variants, including larger intact visual fields and 30Hz ERG amplitudes, suggesting that the truncated mutant protein is able to perform some function, for example through the intact RCC1-like domain, or that a role exists for constitutive *RPGR* within ORF15 mutant photoreceptor cells. It was also proposed that for patients harbouring ORF15 variants, disease severity varied according to the predicted length of the encoded abnormal amino acid sequence; with relatively better retinal function associated with longer wild-type ORF15 amino acid sequences secondary to more downstream variants [9]. Moreover, mutations in the first 14 exons that affect both constitutive *RPGR* and the *RPGR* ORF15 isoforms lead to the most severe disease.

Fahim *et al* [59] studied 98 affected males with 44 different *RPGR* mutations. Patients were grouped into 3 categories of disease severity based on ERG and Humphrey visual field findings. In keeping with Sharon *et al* [9], patients with exon 1-14 variants (often predicted null alleles) had more severe disease than patients with ORF15 variants (predicted potentially translatable transcripts); with ORF15 disease being associated with far greater variability in disease severity.

Several studies have identified that ORF15 variants causing RP are far more frequently located towards the 5' end, whereas variants located towards the 3' end of ORF15 more often result in COD/CORD [60-64]. However, there remains significant intra- and inter-familial variability with examples of both RP and CORD within the same families despite the same underlying sequence variant in *RPGR* [61 65 66], suggesting that genetic and/or environmental modifiers are also influencing phenotype.

### ***RPGR Cone and Cone-Rod Dystrophy***

Disease-causing sequence variants in *RPGR* are the commonest cause of XLCOD and XLCORD [62]. Multiple studies have reported detailed phenotypic findings in both affected males and carrier females [62-64 67-70]. Onset of central visual loss in affected males ranges from the second to the fourth decade, are often myopic, with significant inter- and intra-familial variability both in terms of onset, rate of progression, and rod involvement. This phenotypic heterogeneity is the hallmark of inherited retinal disease and suggests an important role for genetic modifiers and environmental factors.

In keeping with X-linked inheritance, most carrier females are asymptomatic or mildly affected, with a minority of females as severely affected as males [64]. Variability between and within families is believed to be primarily due to varying degrees of skewed X-inactivation, although other genetic modifiers have been proposed [62 64 67-71].

Parafoveal hyperautofluorescent rings are present in some *RPGR* COD and COD male patients on FAF imaging and can progressively increase in size over time. In contrast to RP rings, the size of COD rings is inversely related to pattern ERG P50 amplitude, indicating worse macular cone function with large rings [53 64 72].

To date all reported patients with COD/COD harbour variants in ORF15 – with ORF15 variants causing COD/COD more frequently located towards the 3' end of ORF15 compared to those causing RP [60-64].

### ***RPGR Associated Syndromic Ciliopathy***

Cilia defects cause a wide range of genetic conditions, collectively called ciliopathies. It is now well established that many important retinal proteins have a role in cilia function and retinal dystrophy represents a common phenotype in the clinical spectrum of disease [73]. Further evidence for *RPGR* having an important role in cilia function came from genetic studies where sensorineural hearing loss, bronchiectasis and respiratory tract infections were associated with XLRP caused by an *RPGR* mutation [74]. Additional families have been reported with variable penetrance of these phenotypes, confirming further cases of syndromic disease [50 75 76]. Interestingly, mutations causing syndromic XLRP, to date, are restricted to exons 1-14, suggesting mutations in ORF15 may not be a cause of extra-ocular phenotypes.

## **Therapeutic Options**

### ***Docosahexaenoic acid (DHA) and Vitamin A***

Lipids make up ~ 25% of photoreceptors' dry weight, with photoreceptor outer segment membranes containing equal amounts of proteins and lipids, with 80% or more of lipid composition arising from phospholipids [77]. In human rod outer segments, 20-30% of fatty acids within phospholipids are made up of docosahexaenoic acid (DHA or 22:6  $\omega$  3) [77]; thereby suggesting an important biochemical role in photoreceptors. DHA and vitamin A are both essential components of the visual cycle. Interphotoreceptor retinoid-binding protein (IRBP) can bind either palmitate or DHA resulting in an alteration in affinity for vitamin A isomers [78]. IRBP when located near the retinal pigment epithelium (RPE) predominantly binds palmitate, creating high affinity for 11-*cis* retinal, which is thereby bound and transported to rod outer segments. High levels of DHA in rod outer segments lead to a swap in IRBP fatty acid binding, with subsequent release of 11-*cis* retinal to the outer segments where it forms rhodopsin. Following phototransduction, all-*trans* retinol in the outer segment is bound to IRBP and brought back to the RPE, where DHA is swapped with palmitate thereby resulting in a release of all-*trans* retinol for 11-*cis* retinal [78].

It has therefore been suggested that a lack of DHA, secondary to outer retinal degeneration, may hinder the release of 11-*cis*-retinal, thus giving rise to the hypothesis that DHA levels around photoreceptor outer segments can be increased (in order to facilitate release of 11-*cis* retinal) with DHA supplements or alternatively by increasing retinal levels of 11-*cis* retinal with vitamin A supplementation [79].

A Cochrane review [80] assessed 3 randomised controlled trials on the effectiveness of vitamin A or DHA in RP, including XLRP [81-83]. No clear evidence of benefit with either vitamin A or DHA supplementation was identified on the basis of visual field or ERG parameters. As a result, high dose vitamin A supplements are not routinely recommended to patients. It is generally accepted that eating a healthy and balanced diet, one that is rich in green vegetables and oily fish that will provide good amounts of lutein and omega-3 is instead likely to be of value.

### ***Neuroprotection***

There is evidence from animal studies that ciliary neurotrophic factor (CNTF) delivered either with intravitreal injection of CNTF protein or gene therapy mediated with adeno-associated viral (AAV) vectors exerts a neuroprotective effect on rods, with slowing or halting of retinal degeneration [84]. Recombinant human CNTF has been shown to stimulate cone outer segment regeneration in a rat model of advanced retinal degeneration where rods have already degenerated [85]. In addition, sustained CNTF delivery via implanted devices was shown to preserve cone ERG response and function in the same rat model. [85]

A phase II/III trial has been undertaken of intravitreal implants of encapsulated human retinal pigment epithelium cells engineered to continuously secrete CNTF protein in patients with early (n=68) and late-stage (n=65) RP [86]. Patients were randomly assigned to receive a high- or low-dose implant in 1 eye and sham surgery in the fellow eye. Primary endpoints were change in best-corrected visual acuity at 12 months for late-stage RP and change in visual field sensitivity at 12 months for early RP. Neither study showed therapeutic benefit – with some patients

experiencing loss of retinal sensitivity that was reversible on removal of the implant. However, a pilot study utilising adaptive optics imaging to investigate *in vivo* cone structure in 3 patients with CNTF implants over a 24 month period found that cone density remained stable in eyes with a CNTF implant whereas there was continued cone loss in untreated fellow eyes, suggesting that more sensitive metrics are needed as primary outcome measures in slowly progressive diseases such as RP [87].

### **Gene Therapy**

Successful photoreceptor rescue with *RPGR* ORF15 transgenes has been demonstrated in animal models. Hong *et al* [88] generated a transgenic mouse model that carried mouse *RPGR* ORF15 variant on an *RPGR* null background. The selected *RPGR* ORF15 variant had a 654 base pair deletion within the repetitive purine rich region. Protein expression levels 20% that of wild-type was observed with localisation to the connecting cilia, sufficient for structural and functional rescue of photoreceptors. Another more recent study in *RPGR* null mice has been carried out via subretinally injected AAV vector mediated delivery of two shortened human *RPGR* ORF15 transgenes [89]. The repetitive purine rich region was shortened by 378 base pairs for the first transgene and 942 base pairs for the second transgene. Protein expression followed with both versions of transgene. Appropriate subcellular localisation to the connecting cilia and comparable immunofluorescence signal intensity to wild type was seen with the longer protein, with structural and functional rescue of photoreceptors. A much weaker immunofluorescence signal was however obtained with the shorter gene. A greater efficacy is anticipated with the moderately shortened yet functional version of human *RPGR* ORF15 transgene

compared with the wild-type gene, as the long and repetitive purine rich region present in full length *RPGR* ORF15 is less stable and this may affect the efficacy of gene transfer to photoreceptor cell nuclei. The improved efficacy would be favourable for future human gene therapy trials.

XLPRA1 and XLPRA2 canine models have been successfully rescued with subretinal injection of AAV delivering human *RPGR ORF15* [47]. Post-treatment monitoring with *in vivo* OCT imaging demonstrated a preserved ONL and greater inner segment ellipsoid layer integrity in the retina exposed to vector compared to adjacent un-injected retina, in both XLPRA1 and XLPRA2. These findings were confirmed with histopathology, whereby prevention or reversal of opsin mislocalisation was observed only in the subretinally treated areas. The development of retinal degeneration was prevented with early treatment in XLPRA1, whereas in XLPRA2, due to the earlier onset of this phenotype, intervention during disease progression allowed morphological restoration of remaining photoreceptors [47].

## **Conclusions**

The successful rescue in the aforementioned animal models and the safety and efficacy demonstrated in previous gene therapy trials for Leber Congenital Amaurosis associated with *RPE65* deficiency [90-92] have paved the way for several groups around the world to prepare for Phase I/II gene replacement trials in the near future. However, there is a limiting lack of robust natural history data in large genetically proven groups of patients with XLRP and XLCORD due to *RPGR*. These data are needed in order to design clinical trials of planned gene replacement



therapy. As observed with the CNTF clinical trial, novel outcome metrics are needed in such relatively slowly progressive disease to sensitively detect change in a timely and robust fashion, which may include quantitative retinal imaging with OCT and adaptive optics scanning light ophthalmoscopy. The significant progress made in understanding disease-mechanisms and treatment modalities are exciting and make the aim of future targeted treatments a realistic possibility [93].

**Financial Support:** Supported by grants from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology (UK), Fight For Sight (UK), Moorfields Eye Hospital Special Trustees (UK), Moorfields Eye Charity (UK), the Foundation Fighting Blindness (USA), Retinitis Pigmentosa Fighting Blindness (UK), and NIH (R01EY017607) (USA). Michel Michaelides is supported by an FFB Career Development Award.

## **References**

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. *BMJ open* 2014;**4**(2):e004015 doi: 10.1136/bmjopen-2013-004015[published Online First: Epub Date]].
2. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *The Lancet* 2006;**368**(9549):1795-809 doi: 10.1016/s0140-6736(06)69740-7[published Online First: Epub Date]].
3. Hamel C. Retinitis pigmentosa. *Orphanet journal of rare diseases* 2006;**1**:40 doi: 10.1186/1750-1172-1-40[published Online First: Epub Date]].
4. Xu Y, Guan L, Shen T, et al. Mutations of 60 known causative genes in 157 families with retinitis pigmentosa based on exome sequencing. *Human genetics* 2014;**133**(10):1255-71 doi: 10.1007/s00439-014-1460-2[published Online First: Epub Date]].

5. You QS, Xu L, Wang YX, et al. Prevalence of retinitis pigmentosa in North China: the Beijing Eye Public Health Care Project. *Acta ophthalmologica* 2013;**91**(6):e499-500 doi: 10.1111/aos.12163[published Online First: Epub Date]].
6. Haim M. Epidemiology of retinitis pigmentosa in Denmark. *Acta Ophthalmol Scand Suppl* 2002;**233**(233):1-34
7. Shu X, Black GC, Rice JM, et al. RPGR mutation analysis and disease: an update. *Human mutation* 2007;**28**(4):322-8 doi: 10.1002/humu.20461[published Online First: Epub Date]].
8. Pelletier V, Jambou M, Delphin N, et al. Comprehensive survey of mutations in RP2 and RPGR in patients affected with distinct retinal dystrophies: genotype-phenotype correlations and impact on genetic counseling. *Human mutation* 2007;**28**(1):81-91 doi: 10.1002/humu.20417[published Online First: Epub Date]].
9. Sharon D, Sandberg MA, Rabe VW, Stillberger M, Dryja TP, Berson EL. RP2 and RPGR mutations and clinical correlations in patients with X-linked retinitis pigmentosa. *Am J Hum Genet* 2003;**73**(5):1131-46 doi: 10.1086/379379[published Online First: Epub Date]].
10. Hardcastle AJ, Thiselton DL, Van Maldergem L, et al. Mutations in the RP2 gene cause disease in 10% of families with familial X-linked retinitis pigmentosa assessed in this study. *American Journal of Human Genetics* 1999;**64**(4):1210-15 doi: Doi 10.1086/302325[published Online First: Epub Date]].
11. Breuer DK, Yashar BM, Filippova E, et al. A comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa. *Am J Hum Genet* 2002;**70**(6):1545-54 doi: 10.1086/340848[published Online First: Epub Date]].
12. Schwahn U, Lenzner S, Dong J, et al. Positional cloning of the gene for X-linked retinitis pigmentosa 2. *Nature genetics* 1998;**19**(4):327-32 doi: 10.1038/1214[published Online First: Epub Date]].
13. Webb TR, Parfitt DA, Gardner JC, et al. Deep intronic mutation in OFD1, identified by targeted genomic next-generation sequencing, causes a severe form of X-linked retinitis pigmentosa (RP23). *Hum Mol Genet* 2012;**21**(16):3647-54 doi: 10.1093/hmg/dds194[published Online First: Epub Date]].
14. Meindl A, Dry K, Herrmann K, et al. A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3). *Nature genetics* 1996;**13**(1):35-42 doi: 10.1038/ng0596-35[published Online First: Epub Date]].
15. Bischoff FR, Ponstingl H. Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCC1. *Nature* 1991;**354**(6348):80-2 doi: 10.1038/354080a0[published Online First: Epub Date]].
16. Hadjebi O, Casas-Terradellas E, Garcia-Gonzalo FR, Rosa JL. The RCC1 superfamily: from genes, to function, to disease. *Biochim Biophys Acta* 2008;**1783**(8):1467-79 doi: 10.1016/j.bbamcr.2008.03.015[published Online First: Epub Date]].
17. Vervoort R, Lennon A, Bird AC, et al. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. *Nature genetics* 2000;**25**(4):462-66

18. Shu X, Wright A. Retinitis Pigmentosa GTPase Regulator variant database, 2009
19. Fokkema IFAC, den Dunnen JT, Taschner PEM. LOVD: Easy creation of a locus-specific sequence variation database using an "LSDB-in-a-Box" approach. *Human mutation* 2005;**26**(2):63-68 doi: 10.1002/humu.20201[published Online First: Epub Date]].
20. Yan D, Swain PK, Brueuer D, Tucker RM, Wu W, Fujita R. Biochemical characterization and subcellular localization of the mouse retinitis pigmentosa GTPase regular (mRpgr). *Journal of Biological Chemistry* 1998;**273**:19656
21. Hong DH, Li T. Complex expression pattern of RPGR reveals a role for purine-rich exonic splicing enhancers. *Invest Ophthalmol Vis Sci* 2002;**43**(11):3373-82
22. Kirschner R, Rosenberg T, Schultz-Heienbrok R, et al. RPGR transcription studies in mouse and human tissues reveal a retina-specific isoform that is disrupted in a patient with X-linked retinitis pigmentosa. *Human Molecular Genetics* 1999;**8**(8):1571-78 doi: DOI 10.1093/hmg/8.8.1571[published Online First: Epub Date]].
23. Schmid F, Glaus E, Cremers FP, Kloeckener-Gruissem B, Berger W, Neidhardt J. Mutation- and tissue-specific alterations of RPGR transcripts. *Invest Ophthalmol Vis Sci* 2010;**51**(3):1628-35 doi: 10.1167/iovs.09-4031[published Online First: Epub Date]].
24. Hong DH, Pawlyk B, Sokolov M, et al. RPGR isoforms in photoreceptor connecting cilia and the transitional zone of motile cilia. *Invest Ophthalmol Vis Sci* 2003;**44**(6):2413-21 doi: 10.1167/iovs.02-1206[published Online First: Epub Date]].
25. He S, Parapuram SK, Hurd TW, et al. Retinitis Pigmentosa GTPase Regulator (RPGR) protein isoforms in mammalian retina: insights into X-linked Retinitis Pigmentosa and associated ciliopathies. *Vision research* 2008;**48**(3):366-76 doi: 10.1016/j.visres.2007.08.005[published Online First: Epub Date]].
26. Sharon D, Bruns GA, McGee TL, Sandberg MA, Berson EL, Dryja TP. X-linked retinitis pigmentosa: mutation spectrum of the RPGR and RP2 genes and correlation with visual function. *Invest Ophthalmol Vis Sci* 2000;**41**(9):2712-21
27. Vervoort R, Wright AF. Mutations of RPGR in X-linked retinitis pigmentosa (RP3). *Human mutation* 2002;**19**(5):486-500 doi: 10.1002/humu.10057[published Online First: Epub Date]].
28. Hong DH, Yue G, Adamian M, Li T. Retinitis pigmentosa GTPase regulator (RPGRr)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium. *The Journal of biological chemistry* 2001;**276**(15):12091-9 doi: 10.1074/jbc.M009351200[published Online First: Epub Date]].
29. Murga-Zamalloa C, Swaroop A, Khanna H. Multiprotein complexes of Retinitis Pigmentosa GTPase regulator (RPGR), a ciliary protein mutated in X-linked Retinitis Pigmentosa (XLRP). *Adv Exp Med Biol* 2010;**664**:105-14 doi: 10.1007/978-1-4419-1399-9\_13[published Online First: Epub Date]].
30. Khanna H, Hurd TW, Lillo C, et al. RPGR-ORF15, which is mutated in retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport

- proteins. *The Journal of biological chemistry* 2005;**280**(39):33580-7 doi: 10.1074/jbc.M505827200[published Online First: Epub Date]].
31. Khanna H, Davis EE, Murga-Zamalloa CA, et al. A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies. *Nature genetics* 2009;**41**(6):739-45 doi: 10.1038/ng.366[published Online First: Epub Date]].
  32. Linari M, Ueffing M, Manson F, Wright A, Meitinger T, Becker J. The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase. *Proceedings of the National Academy of Sciences of the United States of America* 1999;**96**(4):1315-20
  33. Wright RN, Hong DH, Perkins B. RprgrORF15 connects to the usher protein network through direct interactions with multiple whirlin isoforms. *Invest Ophthalmol Vis Sci* 2012;**53**(3):1519-29 doi: 10.1167/iovs.11-8845[published Online First: Epub Date]].
  34. Otto EA, Loeys B, Khanna H, et al. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. *Nature genetics* 2005;**37**(3):282-8 doi: 10.1038/ng1520[published Online First: Epub Date]].
  35. Murga-Zamalloa CA, Atkins SJ, Peranen J, Swaroop A, Khanna H. Interaction of retinitis pigmentosa GTPase regulator (RPGR) with RAB8A GTPase: implications for cilia dysfunction and photoreceptor degeneration. *Hum Mol Genet* 2010;**19**(18):3591-8 doi: 10.1093/hmg/ddq275[published Online First: Epub Date]].
  36. Shu X, Fry AM, Tulloch B, et al. RPGR ORF15 isoform co-localizes with RPGRIP1 at centrioles and basal bodies and interacts with nucleophosmin. *Hum Mol Genet* 2005;**14**(9):1183-97 doi: 10.1093/hmg/ddi129[published Online First: Epub Date]].
  37. Adamian M, Pawlyk BS, Hong DH, Berson EL. Rod and cone opsin mislocalization in an autopsy eye from a carrier of X-linked retinitis pigmentosa with a Gly436Asp mutation in the RPGR gene. *Am J Ophthalmol* 2006;**142**(3):515-8 doi: 10.1016/j.ajo.2006.03.061[published Online First: Epub Date]].
  38. Thompson DA, Khan NW, Othman MI, et al. Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGR-ORF15. *PloS one* 2012;**7**(5):e35865 doi: 10.1371/journal.pone.0035865[published Online First: Epub Date]].
  39. Hong DH, Pawlyk BS, Shang J, Sandberg MA, Berson EL, Li T. A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). *Proceedings of the National Academy of Sciences of the United States of America* 2000;**97**(7):3649-54 doi: 10.1073/pnas.060037497[published Online First: Epub Date]].
  40. Beltran WA, Hammond P, Acland GM, Aguirre GD. A frameshift mutation in RPGR exon ORF15 causes photoreceptor degeneration and inner retina remodeling in a model of X-linked retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2006;**47**(4):1669-81 doi: 10.1167/iovs.05-0845[published Online First: Epub Date]].
  41. Beltran WA, Acland GM, Aguirre GD. Age-dependent disease expression determines remodeling of the retinal mosaic in carriers of RPGR exon

- ORF15 mutations. *Invest Ophthalmol Vis Sci* 2009;**50**(8):3985-95 doi: 10.1167/iovs.08-3364[published Online First: Epub Date]].
42. Nemet I, Ropelewski P, Imanishi Y. Rhodopsin Trafficking and Mistrafficking: Signals, Molecular Components, and Mechanisms. *Progress in molecular biology and translational science* 2015;**132**:39-71 doi: 10.1016/bs.pmbts.2015.02.007[published Online First: Epub Date]].
  43. Alfinito PD, Townes-Anderson E. Activation of mislocalized opsin kills rod cells: a novel mechanism for rod cell death in retinal disease. *Proceedings of the National Academy of Sciences of the United States of America* 2002;**99**(8):5655-60 doi: 10.1073/pnas.072557799[published Online First: Epub Date]].
  44. Tam BM, Xie G, Oprian DD, Moritz OL. Mislocalized rhodopsin does not require activation to cause retinal degeneration and neurite outgrowth in *Xenopus laevis*. *J Neurosci* 2006;**26**(1):203-9 doi: 10.1523/jneurosci.3849-05.2006[published Online First: Epub Date]].
  45. Ferreira PA, Nakayama TA, Pak WL, Travis GH. Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin. *Nature* 1996;**383**(6601):637-40 doi: DOI 10.1038/383637a0[published Online First: Epub Date]].
  46. Zhang Q, Acland GM, Wu WX, et al. Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. *Human Molecular Genetics* 2002;**11**(9):993-1003 doi: Doi 10.1093/Hmg/11.9.993[published Online First: Epub Date]].
  47. Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. *Proceedings of the National Academy of Sciences of the United States of America* 2012;**109**(6):2132-7 doi: 10.1073/pnas.1118847109[published Online First: Epub Date]].
  48. Huang WC, Wright AF, Roman AJ, et al. RPGR-associated retinal degeneration in human X-linked RP and a murine model. *Invest Ophthalmol Vis Sci* 2012;**53**(9):5594-608 doi: 10.1167/iovs.12-10070[published Online First: Epub Date]].
  49. Flaxel CJ, Jay M, Thiselton DL, et al. Difference between RP2 and RP3 phenotypes in X linked retinitis pigmentosa. *Br J Ophthalmol* 1999;**83**(10):1144-8
  50. Koenekoop RK, Loyer M, Hand CK, et al. Novel RPGR mutations with distinct retinitis pigmentosa phenotypes in French-Canadian families. *Am J Ophthalmol* 2003;**136**(4):678-87
  51. Kousal B, Skalicka P, Valesova L, et al. Severe retinal degeneration in women with a c.2543del mutation in ORF15 of the RPGR gene. *Mol Vis* 2014;**20**:1307-17
  52. Rozet JM, Perrault I, Gigarel N, et al. Dominant X linked retinitis pigmentosa is frequently accounted for by truncating mutations in exon ORF15 of the RPGR gene. *Journal of medical genetics* 2002;**39**(4):284-5
  53. Robson AG, Michaelides M, Saihan Z, et al. Functional characteristics of patients with retinal dystrophy that manifest abnormal parafoveal annuli of high density fundus autofluorescence; a review and update. *Doc Ophthalmol* 2008;**116**(2):79-89 doi: 10.1007/s10633-007-9087-4[published Online First: Epub Date]].

54. Robson AG, El-Amir A, Bailey C, et al. Pattern ERG correlates of abnormal fundus autofluorescence in patients with retinitis pigmentosa and normal visual acuity. *Invest Ophthalmol Vis Sci* 2003;**44**(8):3544-50
55. Robson AG, Tufail A, Fitzke F, et al. Serial imaging and structure-function correlates of high-density rings of fundus autofluorescence in retinitis pigmentosa. *Retina* 2011;**31**(8):1670-9 doi: 10.1097/IAE.0b013e318206d155[published Online First: Epub Date]].
56. Hood DC, Lazow MA, Locke KG, Greenstein VC, Birch DG. The Transition Zone between Healthy and Diseased Retina in Patients with Retinitis Pigmentosa. *Investigative Ophthalmology & Visual Science* 2011;**52**(1):101-08 doi: Doi 10.1167/iovs.10-5799[published Online First: Epub Date]].
57. Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa. *JAMA ophthalmology* 2013;**131**(9):1143-50 doi: 10.1001/jamaophthalmol.2013.4160[published Online First: Epub Date]].
58. Birch DG, Locke KG, Felius J, et al. Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa. *Ophthalmology* 2015;**122**(4):833-9 doi: 10.1016/j.ophtha.2014.11.005[published Online First: Epub Date]].
59. Fahim AT, Bowne SJ, Sullivan LS, et al. Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to RPGR mutations. *PloS one* 2011;**6**(8):e23021 doi: 10.1371/journal.pone.0023021[published Online First: Epub Date]].
60. Branham K, Othman M, Brumm M, et al. Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. *Invest Ophthalmol Vis Sci* 2012;**53**(13):8232-7 doi: 10.1167/iovs.12-11025[published Online First: Epub Date]].
61. Yang L, Yin X, Feng L, et al. Novel mutations of RPGR in Chinese retinitis pigmentosa patients and the genotype-phenotype correlation. *PloS one* 2014;**9**(1):e85752 doi: 10.1371/journal.pone.0085752[published Online First: Epub Date]].
62. Michaelides M, Hardcastle AJ, Hunt DM, Moore AT. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. *Surv Ophthalmol* 2006;**51**(3):232-58 doi: 10.1016/j.survophthal.2006.02.007[published Online First: Epub Date]].
63. Demirci FY, Rigatti BW, Wen G, et al. X-linked cone-rod dystrophy (locus COD1): identification of mutations in RPGR exon ORF15. *Am J Hum Genet* 2002;**70**(4):1049-53 doi: 10.1086/339620[published Online First: Epub Date]].
64. Ebenezer ND, Michaelides M, Jenkins SA, et al. Identification of novel RPGR ORF15 mutations in X-linked progressive cone-rod dystrophy (XLCORD) families. *Invest Ophthalmol Vis Sci* 2005;**46**(6):1891-8 doi: 10.1167/iovs.04-1482[published Online First: Epub Date]].
65. Walia S, Fishman G, Swaroop A, et al. Discordant phenotypes in fraternal twins having an identical mutation in exon ORF15 of the RPGR gene. *Arch Ophthalmol* 2008;**126**(3):379-84

66. Ruddle JB, Ebenezer ND, Kearns LS, Mulhall LE, Mackey DA, Hardcastle AJ. RPGR ORF15 genotype and clinical variability of retinal degeneration in an Australian population. *Br J Ophthalmol* 2009;**93**(9):1151-4 doi: 10.1136/bjo.2008.153908[published Online First: Epub Date]].
67. Mears AJ, Hiriyan S, Vervoort R, et al. Remapping of the RP15 locus for X-linked cone-rod degeneration to Xp11.4-p21.1, and identification of a de novo insertion in the RPGR exon ORF15. *Am J Hum Genet* 2000;**67**(4):1000-3 doi: 10.1086/303091[published Online First: Epub Date]].
68. Yang Z, Peachey NS, Moshfeghi DM, et al. Mutations in the RPGR gene cause X-linked cone dystrophy. *Hum Mol Genet* 2002;**11**(5):605-11
69. Ayyagari R, Demirci FY, Liu J, et al. X-linked recessive atrophic macular degeneration from RPGR mutation. *Genomics* 2002;**80**(2):166-71
70. Thiadens AA, Soerjoesing GG, Florijn RJ, et al. Clinical course of cone dystrophy caused by mutations in the RPGR gene. *Graefes Arch Clin Exp Ophthalmol* 2011;**249**(10):1527-35 doi: 10.1007/s00417-011-1789-3[published Online First: Epub Date]].
71. Banin E, Mizrahi-Meissonnier L, Neis R, et al. A non-ancestral RPGR missense mutation in families with either recessive or semi-dominant X-linked retinitis pigmentosa. *American journal of medical genetics. Part A* 2007;**143a**(11):1150-8 doi: 10.1002/ajmg.a.31642[published Online First: Epub Date]].
72. Robson AG, Michaelides M, Luong VA, et al. Functional correlates of fundus autofluorescence abnormalities in patients with RPGR or RIMS1 mutations causing cone or cone rod dystrophy. *Br J Ophthalmol* 2008;**92**(1):95-102 doi: 10.1136/bjo.2007.124008[published Online First: Epub Date]].
73. Wheway G, Parry DA, Johnson CA. The role of primary cilia in the development and disease of the retina. *Organogenesis* 2014;**10**(1):69-85 doi: 10.4161/org.26710[published Online First: Epub Date]].
74. Zito I, Downes SM, Patel RJ, et al. RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections. *Journal of medical genetics* 2003;**40**(8):609-15
75. Iannaccone A, Breuer DK, Wang XF, et al. Clinical and immunohistochemical evidence for an X linked retinitis pigmentosa syndrome with recurrent infections and hearing loss in association with an RPGR mutation. *Journal of medical genetics* 2003;**40**(11):e118
76. Moore A, Escudier E, Roger G, et al. RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. *Journal of medical genetics* 2006;**43**(4):326-33 doi: 10.1136/jmg.2005.034868[published Online First: Epub Date]].
77. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. *Prog Lipid Res* 1983;**22**(2):79-131
78. Wolf G. Transport of retinoids by the interphotoreceptor retinoid-binding protein. *Nutr Rev* 1998;**56**(5 Pt 1):156-8
79. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. *Arch Ophthalmol*

- 2004;**122**(9):1306-14 doi: 10.1001/archophth.122.9.1306[published Online First: Epub Date]].
80. Rayapudi S, Schwartz SG, Wang X, Chavis P. Vitamin A and fish oils for retinitis pigmentosa. The Cochrane database of systematic reviews 2013;**12**:Cd008428 doi: 10.1002/14651858.CD008428.pub2[published Online First: Epub Date]].
  81. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;**111**(6):761-72
  82. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004;**122**(9):1297-305 doi: 10.1001/archophth.122.9.1297[published Online First: Epub Date]].
  83. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004;**137**(4):704-18 doi: 10.1016/j.ajo.2003.10.045[published Online First: Epub Date]].
  84. Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Progress in retinal and eye research 2012;**31**(2):136-51 doi: 10.1016/j.preteyeres.2011.11.005[published Online First: Epub Date]].
  85. Li Y, Tao W, Luo L, et al. CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration. PloS one 2010;**5**(3):e9495 doi: 10.1371/journal.pone.0009495[published Online First: Epub Date]].
  86. Birch DG, Weleber RG, Duncan JL, Jaffe GJ, Tao W, Ciliary Neurotrophic Factor Retinitis Pigmentosa Study G. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol 2013;**156**(2):283-92 e1 doi: 10.1016/j.ajo.2013.03.021[published Online First: Epub Date]].
  87. Talcott KE, Ratnam K, Sundquist SM, et al. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci 2011;**52**(5):2219-26 doi: 10.1167/iovs.10-6479[published Online First: Epub Date]].
  88. Hong DH, Pawlyk BS, Adamian M, Sandberg MA, Li T. A single, abbreviated RPGR-ORF15 variant reconstitutes RPGR function in vivo. Invest Ophthalmol Vis Sci 2005;**46**(2):435-41 doi: 10.1167/iovs.04-1065[published Online First: Epub Date]].
  89. Pawlyk BS, Bulgakov OV, Sun X, et al. Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of x-linked retinitis pigmentosa. Gene therapy 2015 doi: 10.1038/gt.2015.93[published Online First: Epub Date]].
  90. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;**358**(21):2231-9 doi: 10.1056/NEJMoa0802268[published Online First: Epub Date]].
  91. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;**358**(21):2240-8 doi: 10.1056/NEJMoa0802315[published Online First: Epub Date]].



92. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. *Human gene therapy* 2008;**19**(10):979-90 doi: 10.1089/hum.2008.107[published Online First: Epub Date]].
93. Smith J, Ward D, Michaelides M, Moore AT, Simpson S. New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review. *Eye* 2015 doi: 10.1038/eye.2015.115[published Online First: Epub Date]].